CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

thymalfasin

Trade name: zadaxin

Small moleculeexperimental

Clinical trial activity

41 trials · 46 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
27
Phase 3
7
Phase 4
6

Earliest trial started Nov 2, 1999 (NCT00001036)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

    Interaction mechanism poorly understood. N-terminus of thymalfasin interacts with negative regions of membranes due to the exposure of phosphatidylserine. Once N-terminus inserted into the membrane, the rest may interact with nearby proteins acting as effectors and causing a biological signaling cascade. It induces maturation in T-cells and in dendritic cells. Induces gene expression of Toll-like receptors, interleukin (IL-12) and cytokines. Binds to plasma protein albumin (HSA).

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O
Mol. weight
3108.31 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alpha1-thymosin
  • emz702
  • emz702
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymalfasin
  • thymosin alpha
  • thymosin alpha1
  • thymosin alpha1
  • thymosin alpha1
  • thymosin alpha1
  • thymosin alpha1
  • thymosin alpha 1
  • thymosin alpha 1
  • thymosin alpha 1
  • thymosin alpha(1)
  • zadaxin
  • zadaxin
  • zadaxin
  • zadaxin
  • zadaxin
  • zadaxin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06829355Phase 2Feb 11, 2025Capital Medical University, Chinese Academy of Medical Sciences, Peking University
NCT06821100Phase 1Dec 2, 2024The University of Texas, Dallas
NCT06607926N/AOct 15, 2024Capital Medical University
NCT06573398Phase 2Sep 1, 2024Jiao Tong University
NCT06461910Phase 2Jun 30, 2024Nanjing Medical University
NCT06056804Phase 2Dec 1, 2023Capital Medical University, Chinese Academy of Medical Sciences
NCT05790447Phase 2Apr 1, 2023SciClone Pharmaceuticals, Soochow University
NCT05658692Phase 4Oct 1, 2022Chinese Academy of Medical Sciences, Fudan University, Harbin Medical University, Huazhong University of Science and Technology, Ningbo No. 1 Hospital, Shantou University, Sichuan University, Wenzhou Medical University, Wuhan University, Zhejiang University, Zhengzhou University
NCT05339529N/AJul 1, 2022Capital Medical University, Nanchang University, Nanjing Medical University
NCT04963712Phase 3Sep 30, 2021Fudan University
NCT04487444Phase 2Sep 10, 2020Brown University, Rhode Island Hospital
NCT04428008Early Phase 1 (Phase 1)Jun 30, 2020Davita Clinical Research, Inova Health System, Nephrology Associates of Northern Virginia, Inc.
NCT04320238Phase 3Jan 21, 2020Jiao Tong University
NCT03659578Phase 2Aug 9, 2018Sun Yat-Sen University
NCT02867267Phase 3Feb 17, 2017SciClone Pharmaceuticals, Sun Yat-Sen University
NCT02976740Phase 2Nov 1, 2016Xiamen University
NCT02906163Phase 1/Phase 2 (Phase 2)Oct 1, 2016Azienda Ospedaliera Sant'Andrea, Roma, SciClone Pharmaceuticals
NCT02906150Phase 2Sep 1, 2016SciClone Pharmaceuticals
NCT02883595Phase 4Jun 1, 2016Sun Yat-Sen University
NCT02787447Phase 2May 1, 2016First People's Hospital of Hangzhou
Showing 20 of 41 trials
Page 1 / 3

Organizations

Research & Development (46)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SciClone PharmaceuticalsFor profit10532002
Zhejiang UniversityAcademic/Hospital7532013
Capital Medical UniversityAcademic/Hospital6532013
Chinese Academy of Medical SciencesAcademic/Hospital5122016
Fudan UniversityAcademic/Hospital5222013
Jiao Tong UniversityAcademic/Hospital4232013
Sun Yat-Sen UniversityAcademic/Hospital4442008
Huazhong University of Science and TechnologyAcademic/Hospital3012013
Leadiant Biosciences, Inc.For profit3322002
Peking UniversityAcademic/Hospital3022013
Fifth Hospital of Shijiazhuang CityAcademic/Hospital2012013
Nanjing Medical UniversityAcademic/Hospital2222022
People's Liberation Army of ChinaGovernment2012013
Shanxi Medical UniversityAcademic/Hospital2012013
Southern Medical UniversityAcademic/Hospital2012013
Tsinghua UniversityAcademic/Hospital2012013
Yanbian UniversityAcademic/Hospital2012013
Azienda Ospedaliera Sant'Andrea, RomaAcademic/Hospital1012016
Azienda Ospedaliera S Giovanni BattistaAcademic/Hospital1012004
Bangladesh Medical UniversityAcademic/Hospital1012011
46 organizations
Page 1 / 3